EU/US/CTAD Task Force

Lessons Learned from Recent and Current Alzheimer's Prevention Trials

P. Aisen, J. Touchon, R. Amariglio, S. Andrieu, R. Bateman, John C.S. Breitner, M. Donohue, B. Dunn, R. Doody, N. Fox, S. Gauthier, M. Grundman, S. Hendrix, C. Ho, M. Isaac, R. Raman, Paul B Rosenberg, R. Schindler, L. Schneider, R. Sperling & 4 others P. Tariot, K. Welsh-Bohmer, M. Weiner, B. Vellas

Research output: Contribution to journalArticle

Abstract

At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.

Original languageEnglish (US)
Pages (from-to)116-124
Number of pages9
JournalThe journal of prevention of Alzheimer's disease
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Advisory Committees
Alzheimer Disease
Clinical Trials
Cognition
Disease Progression
Industry
Biomarkers
Research Personnel
Outcome Assessment (Health Care)
Therapeutics

Keywords

  • Alzheimer’s disease
  • clinical trials
  • cognitive composites
  • cognitive outcome measures
  • informant-reported outcome measures
  • mild behavioral impairment
  • molecular imaging
  • patient-reported outcome measures
  • secondary prevention trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

EU/US/CTAD Task Force : Lessons Learned from Recent and Current Alzheimer's Prevention Trials. / Aisen, P.; Touchon, J.; Amariglio, R.; Andrieu, S.; Bateman, R.; Breitner, John C.S.; Donohue, M.; Dunn, B.; Doody, R.; Fox, N.; Gauthier, S.; Grundman, M.; Hendrix, S.; Ho, C.; Isaac, M.; Raman, R.; Rosenberg, Paul B; Schindler, R.; Schneider, L.; Sperling, R.; Tariot, P.; Welsh-Bohmer, K.; Weiner, M.; Vellas, B.

In: The journal of prevention of Alzheimer's disease, Vol. 4, No. 2, 01.01.2017, p. 116-124.

Research output: Contribution to journalArticle

Aisen, P, Touchon, J, Amariglio, R, Andrieu, S, Bateman, R, Breitner, JCS, Donohue, M, Dunn, B, Doody, R, Fox, N, Gauthier, S, Grundman, M, Hendrix, S, Ho, C, Isaac, M, Raman, R, Rosenberg, PB, Schindler, R, Schneider, L, Sperling, R, Tariot, P, Welsh-Bohmer, K, Weiner, M & Vellas, B 2017, 'EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials', The journal of prevention of Alzheimer's disease, vol. 4, no. 2, pp. 116-124. https://doi.org/10.14283/jpad.2017.13
Aisen, P. ; Touchon, J. ; Amariglio, R. ; Andrieu, S. ; Bateman, R. ; Breitner, John C.S. ; Donohue, M. ; Dunn, B. ; Doody, R. ; Fox, N. ; Gauthier, S. ; Grundman, M. ; Hendrix, S. ; Ho, C. ; Isaac, M. ; Raman, R. ; Rosenberg, Paul B ; Schindler, R. ; Schneider, L. ; Sperling, R. ; Tariot, P. ; Welsh-Bohmer, K. ; Weiner, M. ; Vellas, B. / EU/US/CTAD Task Force : Lessons Learned from Recent and Current Alzheimer's Prevention Trials. In: The journal of prevention of Alzheimer's disease. 2017 ; Vol. 4, No. 2. pp. 116-124.
@article{c86ef3fc9e2741ef8eeb3f031221b6c0,
title = "EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials",
abstract = "At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.",
keywords = "Alzheimer’s disease, clinical trials, cognitive composites, cognitive outcome measures, informant-reported outcome measures, mild behavioral impairment, molecular imaging, patient-reported outcome measures, secondary prevention trials",
author = "P. Aisen and J. Touchon and R. Amariglio and S. Andrieu and R. Bateman and Breitner, {John C.S.} and M. Donohue and B. Dunn and R. Doody and N. Fox and S. Gauthier and M. Grundman and S. Hendrix and C. Ho and M. Isaac and R. Raman and Rosenberg, {Paul B} and R. Schindler and L. Schneider and R. Sperling and P. Tariot and K. Welsh-Bohmer and M. Weiner and B. Vellas",
year = "2017",
month = "1",
day = "1",
doi = "10.14283/jpad.2017.13",
language = "English (US)",
volume = "4",
pages = "116--124",
journal = "The journal of prevention of Alzheimer's disease",
issn = "2426-0266",
publisher = "Springer International Publishing AG",
number = "2",

}

TY - JOUR

T1 - EU/US/CTAD Task Force

T2 - Lessons Learned from Recent and Current Alzheimer's Prevention Trials

AU - Aisen, P.

AU - Touchon, J.

AU - Amariglio, R.

AU - Andrieu, S.

AU - Bateman, R.

AU - Breitner, John C.S.

AU - Donohue, M.

AU - Dunn, B.

AU - Doody, R.

AU - Fox, N.

AU - Gauthier, S.

AU - Grundman, M.

AU - Hendrix, S.

AU - Ho, C.

AU - Isaac, M.

AU - Raman, R.

AU - Rosenberg, Paul B

AU - Schindler, R.

AU - Schneider, L.

AU - Sperling, R.

AU - Tariot, P.

AU - Welsh-Bohmer, K.

AU - Weiner, M.

AU - Vellas, B.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.

AB - At a meeting of the EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force in December 2016, an international group of investigators from industry, academia, and regulatory agencies reviewed lessons learned from ongoing and planned prevention trials, which will help guide future clinical trials of AD treatments, particularly in the pre-clinical space. The Task Force discussed challenges that need to be addressed across all aspects of clinical trials, calling for innovation in recruitment and retention, infrastructure development, and the selection of outcome measures. While cognitive change provides a marker of disease progression across the disease continuum, there remains a need to identify the optimal assessment tools that provide clinically meaningful endpoints. Patient- and informant-reported assessments of cognition and function may be useful but present additional challenges. Imaging and other biomarkers are also essential to maximize the efficiency of and the information learned from clinical trials.

KW - Alzheimer’s disease

KW - clinical trials

KW - cognitive composites

KW - cognitive outcome measures

KW - informant-reported outcome measures

KW - mild behavioral impairment

KW - molecular imaging

KW - patient-reported outcome measures

KW - secondary prevention trials

UR - http://www.scopus.com/inward/record.url?scp=85054930234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054930234&partnerID=8YFLogxK

U2 - 10.14283/jpad.2017.13

DO - 10.14283/jpad.2017.13

M3 - Article

VL - 4

SP - 116

EP - 124

JO - The journal of prevention of Alzheimer's disease

JF - The journal of prevention of Alzheimer's disease

SN - 2426-0266

IS - 2

ER -